Cited 26 times in

Loss of ACSS2 expression predicts poor prognosis in patients with gastric cancer.

DC Field Value Language
dc.contributor.authorHur, H-
dc.contributor.authorKim, YB-
dc.contributor.authorHam, IH-
dc.contributor.authorLee, D-
dc.date.accessioned2017-03-14T05:59:32Z-
dc.date.available2017-03-14T05:59:32Z-
dc.date.issued2015-
dc.identifier.issn0022-4790-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/13510-
dc.description.abstractBACKGROUND: Recent studies have demonstrated that acetyl-CoA synthetase 2 (ACSS2) plays a critical role in cancer cell survival; however, the role of ACSS2 in gastric carcinogenesis has not been determined.

METHODS: We investigated the expression of ACSS2 in human gastric cancer (GC) tissues using immunohistochemistry, and analyzed its clinicopathological correlation and prognostic relevance.

RESULTS: Among 350 GCs, 219 cases (62.6%) were classified as ACSS2-low, whereas 131 cases (37.4%) were ACSS2-high. Loss of ACSS2 expression (ACSS2-low) was more frequently observed in undifferentiated histology (P = 0.002), in cases with MLH1-loss (P = 0.003), and in cases with SIRT3-low (P < 0.001). The ACSS2-low cases showed significantly lower mean disease-free survival (DFS, 68.5 vs. 81.8 months; P = 0.025) and overall survival (OS, 73.5 vs. 86.6 months; P = 0.029). In multivariate analysis, loss of ACSS2 expression was identified as one of the independent prognostic factors predicting worse DFS (HR: 1.547, P = 0.018) and OS (HR: 1.476, P = 0.036).

CONCLUSIONS: We revealed that the loss of ACSS2 expression is a reliable independent poor prognostic factor in GC. Our results may expand our understanding of the involvement of glucose metabolism, including the role of ACSS2, in the pathogenesis of GC.
-
dc.language.isoen-
dc.subject.MESHAcetate-CoA Ligase/metabolism-
dc.subject.MESHAdenocarcinoma/metabolism-
dc.subject.MESHAdenocarcinoma/mortality-
dc.subject.MESHAdenocarcinoma/pathology-
dc.subject.MESHAdenocarcinoma, Mucinous/metabolism-
dc.subject.MESHAdenocarcinoma, Mucinous/mortality-
dc.subject.MESHAdenocarcinoma, Mucinous/pathology-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAged, 80 and over-
dc.subject.MESHBiomarkers, Tumor/metabolism-
dc.subject.MESHCarcinoma, Signet Ring Cell/metabolism-
dc.subject.MESHCarcinoma, Signet Ring Cell/mortality-
dc.subject.MESHCarcinoma, Signet Ring Cell/pathology-
dc.subject.MESHFemale-
dc.subject.MESHFollow-Up Studies-
dc.subject.MESHHumans-
dc.subject.MESHImmunoenzyme Techniques-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoplasm Invasiveness-
dc.subject.MESHNeoplasm Staging-
dc.subject.MESHPrognosis-
dc.subject.MESHStomach Neoplasms/metabolism-
dc.subject.MESHStomach Neoplasms/mortality-
dc.subject.MESHStomach Neoplasms/pathology-
dc.subject.MESHSurvival Rate-
dc.subject.MESHTissue Array Analysis-
dc.subject.MESHYoung Adult-
dc.titleLoss of ACSS2 expression predicts poor prognosis in patients with gastric cancer.-
dc.typeArticle-
dc.identifier.pmid26381042-
dc.contributor.affiliatedAuthor허, 훈-
dc.contributor.affiliatedAuthor김, 영배-
dc.contributor.affiliatedAuthor이, 다근-
dc.type.localJournal Papers-
dc.identifier.doi10.1002/jso.24043-
dc.citation.titleJournal of surgical oncology-
dc.citation.volume112-
dc.citation.number6-
dc.citation.date2015-
dc.citation.startPage585-
dc.citation.endPage591-
dc.identifier.bibliographicCitationJournal of surgical oncology, 112(6). : 585-591, 2015-
dc.identifier.eissn1096-9098-
dc.relation.journalidJ000224790-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Surgery
Journal Papers > School of Medicine / Graduate School of Medicine > Pathology
Files in This Item:

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse